BioSystem Development Closes a Near $1 Million Investment Round

MADISON, Wis.--(BUSINESS WIRE)--BioSystem Development, a privately held life science analytics company, announces a recently completed investment round that raised $978,000 (USD) in funding. The proceeds will be used to expand manufacturing infrastructure and to launch new products into the biopharmaceutical development market. Founder and Chief Executive Officer Scott Fulton stated, “We are pleased to close the round. This funding provides us the means to respond to growing market interest and launch several new disruptive AssayMAP products.”

“We are pleased to close the round. This funding provides us the means to respond to growing market interest and launch several new disruptive AssayMAP products.”

Previous investors and new angel investors from Wisconsin, Illinois, North Carolina, California and New York participated in this round. Jo Wegstein, President of ProZyme, Inc, and a key investor commented, “ProZyme is collaborating with BioSystem Development to broadly incorporate AssayMAP® technology in our GlykoPrep™ platform. I have experienced first-hand the value of this partnership with our Glyko®-technology to create enabling solutions for our customers that are robust, automatable and straightforward to implement. As an individual investor, I see the AssayMAP platform as a far-reaching technology that increases the throughput of complex analytical workflows in the critical path for new drug discovery, process development, product characterization and manufacturing controls.”

BioSystem Development, established in 2002, creates, manufactures and markets tools and products to meet the critical and growing analytical needs of pharmaceutical development. The company’s AssayMAP platform, based on disposable micro-chromatography cartridges and automation, enables high throughput solutions for bioprocess development, biomarkers and general life science research that reduce development time and increase efficiency.